Pfizer can capitalize on drug withdrawal
499909
Pfizer Inc., the world&#39;s biggest drugmaker, may benefit from Merck &amp; Co.&#39;s withdrawal of Vioxx because Pfizer&#39;s competing pain medicine Celebrex hasn&#39;t been linked to increased risk of heart attacks and strokes.
477244
Pfizer Inc. PFE.N, the world's  biggest drugmaker, on Wednesday said third-quarter earnings  rose on higher sales of key medicines and favorable foreign  exchange factors.
707565
Pfizer Inc  reported a higher-than-expected fourth-quarter profit on Wednesday, helped by lower taxes, a weak dollar and demand for drugs to treat nerve pain, kidney cancer and to help smokers kick the habit.
314927
The move may mark the beginning of a bigger retrenchment by Pfizer and the rest of the drug industry.
693310
The Pfizer painkillers Celebrex and Bextra experienced a jump in sales immediately after rival Merck&#39;s Vioxx was pulled from the market in late September, but the gains appear to be short
341524
Americans recently were jolted about the safety of their prescription drugs when Merck announced in late September the biggest voluntary withdrawal of a drug in recent memory.
12838
Pfizer Inc. shares staged a rebound Tuesday, spurred in part by what Wall Street viewed as positive publicity about its Celebrex drug.
701173
Pfizer Inc , the world&#39;s largest  drug maker, said on Friday it is in talks with investors about  spinning off its Japanese research and development laboratory,  albeit as a much smaller organization.
63006
When Dr. Sherwin Siff got the news three months ago that the popular painkiller Vioxx was being pulled from the market, he had a good idea its cousins, Celebrex and Bextra, would face problems, too.
49837
The abrupt withdrawal last week of the best-selling painkiller Vioxx is an event rich in ironies and lessons that may ultimately lead to a rethinking of the way drug safety is evaluated in the United States.
362559
Drug investors may be wishing they could pop two pills and feel better in the morning. The latest headache hit last week when Pfizer joined the rash of drug companies announcing problems with their products.
485764
With the sudden failure of torcetrapib, Pfizer Inc.'s most important experimental product, financial analysts predict shares of the world's largest drugmaker could fall from 5 to 25 percent on Monday and that Pfizer will need to buy other products to fill the void.
80950
The abrupt withdrawal last week of the best-selling painkiller Vioxx is an event rich in ironies and lessons.
326837
Last weekâs dramatic withdrawal of the COX-2 inhibitor rofecoxib (Vioxx) is discussed in this weekâs lead editorial in THE LANCET, which comments that more vigilant drug licensing is vital to prevent the endangering of patientsâ health.
287612
Pulling an application for Iressa from the EU makes the drug a has-been.
149032
The stock is feeling some pain these days. However, this drugmaker has enough going for it that the illness shouldn&#39;t last. Amid nervousness over the future of Pfizer&#39;s arthritis pain treatment Celebrex and
556546
Pfizer Inc. PFE.N, the world's  largest drug maker, said on Tuesday it was conducting a  comprehensive review of its operations, but said analyst  speculation it had decided to cut jobs was "premature."